Nurix Therapeutics, Inc. (NRIX)

Market Cap	994.87M
Revenue (ttm)	83.69M
Net Income (ttm)	-244.79M
Shares Out	76.88M
EPS (ttm)	-2.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,680,520
Open	12.61
Previous Close	12.78
Day's Range	12.46 - 13.19
52-Week Range	8.18 - 29.56
Beta	2.34
Analysts	Strong Buy
Price Target	26.29 (+103.17%)
Earnings Date	Oct 9, 2025

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 286
• Stock Exchange: NASDAQ
• Ticker Symbol: NRIX
• Website: https://www.nurixtx.com

Financial Performance

In 2024, Nurix Therapeutics's revenue was $54.55 million, a decrease of -29.15% compared to the previous year's $76.99 million. Losses were -$193.57 million, 34.5% more than in 2023.

Analyst Summary

According to 14 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $26.29, which is an increase of 103.17% from the latest price.

Price Target

$26.29

(103.17% upside)

Analyst Consensus: Strong Buy